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Abstract
In Alternative Lengthening of Telomeres (ALT) cell lines, specific nuclear bodies called APBs (ALT-associated PML bodies)
concentrate telomeric DNA, shelterin components and recombination factors associated with telomere recombination.
Topoisomerase IIIa (Topo III) is an essential telomeric-associated factor in ALT cells. We show here that the binding of Topo
III to telomeric G-overhang is modulated by G-quadruplex formation. Topo III binding to G-quadruplex-forming
oligonucleotides was strongly inhibited by telomestatin, a potent and specific G-quadruplex ligand. In ALT cells,
telomestatin treatment resulted in the depletion of the Topo III/BLM/TRF2 complex and the disruption of APBs and led to
the segregation of PML, shelterin components and Topo III. Interestingly, a DNA damage response was observed at
telomeres in telomestatin-treated cells. These data indicate the importance of G-quadruplex stabilization during telomere
maintenance in ALT cells. The function of TRF2/Topo III/BLM in the resolution of replication intermediates at telomeres is
discussed.
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Introduction
In vertebrates, the telomeres that cap chromosome ends are
composed of tandem repeats of the sequence d(TTAGGG)nwith a 39
single-stranded extension (G-overhang) associated with six protein
factors (TRF1, TRF2, RAP1, TIN2, TPP1 and POT1) that form a
protecting complex (shelterin) essential for genome stability [1].
Telomeres shorten at each round of cell division and cellular
mechanisms that counteract this loss confer indefinite proliferation
potential characteristic of cancerous cells [2]. Two mechanisms have
been reported in the maintenance of telomere length. The first
requires a specialized enzyme, called telomerase, which is able to
copy, as a reverse transcriptase, the short TTAGGG motif at the 39
end of telomeres; the activity of telomerase is tightly controlled by
shelterin [2]. The second mechanism involves recombination
between telomeres, a mechanism known as Alternative Lengthening
of Telomeres (ALT) [3]. ALT cells are characterized by the absence
of telomerase activity, heterogeneous telomere length and the
presence of nuclear foci termed ALT-associated PML bodies (APBs)
that contain telomeric DNA, telomeric proteins TRF1 and TRF2,
and DNA recombination/repair proteins [3].
In vitro, DNA oligonucleotides composed of the G-overhang
DNA sequence may adopt a four-stranded structure called a G-
quadruplex. Both direct and indirect evidence suggests that G-
quadruplexes are also present in eukaryotic cells and that
formation of this structure must be tightly regulated to allow
DNA replication and cell division (for a review, see [4]). The
binding of specific ligands to the telomeric G-quadruplex is a
strategy to alter telomere functions and to inhibit cell growth. A
number of G-quadruplex ligands have been synthesized during the
last decade [5]. These compounds were initially derived from
DNA intercalators [6] and now present selective binding
properties to G-quadruplexes relative to duplex or single-stranded
DNA [5]. The initial therapeutic rationale for use of these
compounds in treatment of cancer was that inhibition of
telomerase activity would inhibit unchecked cell proliferation
[7,8], but several pieces of evidence suggest that these ligands must
be considered as telomere targeting agents rather than simple
telomerase inhibitors [9–11].
The natural product telomestatin, is one of the most potent and
selective G-quadruplex binding small molecules known [12–14].
Treatment with telomestatin impairs telomere replication and
provokes the release of POT1 and TRF2 from telomeres, which
results in loss of single- and double-stranded telomeric DNA and
inhibits growth of tumor cells [15]. However, little is known about
the effect of this compound or other G-quadruplex ligands on
telomerase-negative ALT cell lines, except that telomestatin
inhibits cell proliferation[8,13,16,17].
G-quadruplex ligands also inhibit in vitro the activity of RecQ
helicases WRN and BLM [18]. These helicases are associated with
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6919APBs in ALT cells and interact with shelterin components [19–21].
BLM is known to interact with Topoisomerase IIIa (Topo III) and
two other proteins with OB-fold domains, RMI1 and RMI2, to
form a RTR complex (RecQ/Topo III/RMI) essential to
maintenance of genome stability through its function in the
resolution of recombination intermediates (for recent reviews see
[22,23]). In this complex, Topo III and BLM cooperate to convert
double Holliday junctions (DHJ) to decatenated products in vitro
[24]. RMI1 guides the binding of Topo III [25–27] and RMI2
regulates other protein-protein interactions in the complex [28,29].
The Topo III/BLM complex may function as a repair complex in
response to replication defects and may restart stalled replication
forks [30–32]. Followingcamptothecin treatment, a phosphorylated
form of BLM dissociates from the Topo III/BLM complex at its
PML storage sites and accumulates with c-H2AX at damage sites
during replication [33].
Topo III belongs to the Type IA DNA topoisomerase subfamily,
which is conserved among different organisms; it removes highly
negative supercoils where single-stranded DNA is exposed [34]. In
vitro this access can be provided by altering the secondary structure
of the substrate using hyper-negative supercoiling or by the
addition of single-stranded binding protein (RPA, RMI1) to assist
Topo III binding [27]. Structural studies of E. coli Topo III
revealed that the protein first recognizes the presence of single-
stranded DNA through a specific DNA binding region and then
induces protein rearrangements that activate the tyrosine catalytic
region [35]. This ensures the recognition of the correct type of
DNA by the active site and explains the requirement for cofactors
to generate single-stranded DNA.
Due to the diversity of complex structures that may form at
telomere ends during fork progression, there is a requirement for
factors that modulate topology, t-loop formation and resolution
[36,37]. Among these factors, Topo III is an essential telomeric-
associated component in ALT cells [38,39]. Topo III interacts with
telomeric DNA and forms a complex with TRF2 and BLM at
telomeres in ALT cells [39]. Inhibition of Topo III expression by
Figure 1. Topo III preferentially binds to single-stranded oligonucleotides when compared to G-quadruplex-forming sequences. A,
Competition experiment for Topo III (50 nM) binding to [
32P]-labeled 24C oligonucleotide (20 nM) in the presence of either unlabeled Pu22myc or
Pu22mu (see sequences in Material and Methods) at the indicated concentrations (in mM). B, Quantification of the competition experiments for Topo
III binding to [
32P]-labeled S310 (top), 21G (middle), and 24C (bottom) oligonucleotides (at 20 nM) with increasing concentrations (1 to 1000 nM) of
unlabeled 21G (closed circles), 21Gmu (open circles), Pu22myc (closed triangles), and Pu22mu (open triangles) oligonucleotides. Results correspond
to the mean 6 SD of three determinations. f0 is the initial fraction of DNA bound to Topo III and f the fraction of DNA bound to Topo III at a
determined concentration of the competitor.
doi:10.1371/journal.pone.0006919.g001
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positive cell lines. Moreover, repression of Topo III expression in
ALT cells induced telomere uncapping associated with reduced levels
of TRF2 and BLM proteins [39]. This data suggested that the Topo
III/BLM/TRF2 complex plays a role in the resolution of topological
intermediates that arise during telomere recombination [39].
To examine whether Topo III binding at telomeric sequences
and its localization at APBs is modulated by G-quadruplex
formation, we have used the selective G-quadruplex ligand
telomestatin. We found that Topo III binding is strongly inhibited
by stabilization of G-quadruplex structures and that this ligand
induces the disruption of APBs in ALT cells. This effect mimics the
depletion of Topo III by RNA interference as it induces the
depletion of the Topo III/BLM/TRF2 complex and results in
telomere uncapping as evidenced by DNA damage at telomeres.
We suggest that telomere maintenance in ALT cells may be
particularly sensitive to G-quadruplex formation due to the need
for the Topo III/BLM/TRF2 complex to resolve or modulate
intermediate recombination/replication structures at telomeres.
Materials and Methods
Topo III and POT1 binding assays
Topo IIIa was purified according to a previously published
procedure [40]. Purified recombinant hPOT1, prepared after
baculovirus expression, was a generous gift from Dr. D. Gomez
(Institut de Pharmacologie et de Biologie Structurale, Toulouse,
France).
The oligonucleotides used in the study were:
21G: 59-GGGTTAGGGTTAGGGTTAGGG-39
21G mu3: 59-GGCTTACGGTTAGCGTTAGGG-39
Wt26: 59-TTAGGGTTAGGGTTAGGGTTAGGGTT-39
Pu22myc: 59-GAGGGTGGGGAGGGTGGGGAAG-39
Pu22mu: 59-GAGGGTGAAGAGGGTGGGGAAG-39
24C: 59-CCCTAACCCTAACCCTAACCCTAA-39
S310: 59-CCAGCTCTGCTTTGCATCTTT-39
Oligonucleotides were labelled at the 59 end with [c-
32P]-ATP
using T4 Polynucleotide Kinase (New England BioLabsH).
Electrophoretic mobility shift assays using Topo III or hPOT1
were performed in 10 mL of the following solution: 50 mM
HEPES (pH 7.9), 100 mM NaCl, 0.1 mM EDTA, 4% w/v
sucrose, 2% v/v glycerol, 0.1 mg/mL BSA, 0.02% w/v
bromophenol blue, 20 nM labelled oligonucleotide and Topo III
(50 nM) or hPOT1 (30 nM). For competition assays, the indicated
concentrations of unlabelled oligonucleotides (1, 3, 10, 30, 100,
300, or 1000 nM) were added to the reaction mixture. For binding
inhibition assays, the indicated concentrations of telomestatin were
added in a volume of 1 mL. Telomestatin was prepared at 5 mM
in 1:1 DMSO/MetOH and was dissolved to 100 mM in DMSO
and further with water. The reaction mixture was incubated at
room temperature for 30 min. Each individual mixture was
separated immediately by electrophoresis on 1% agarose gels in
Figure 2. Telomestatin inhibits Topo III and POT1 binding to telomeric G-overhangs. A, Bandshift assay using purified Topo III (50 nM)
and [32P]-labeled Wt26 in the presence of the indicated concentrations of telomestatin. B, Bandshift assay using purified Topo III (50 nM) and [32P]-
labeled S310 (20 nM) in the presence of the indicated concentrations of telomestatin. C, Bandshift assay using POT1 (30 nM) and [32P]-labeled Wt26
(20 nM) in the presence of the indicated concentrations of telomestatin. Telomestatin inhibits Topo III and POT1 binding to Wt26, which forms a G-
quadruplex, but not to S310, which does not.
doi:10.1371/journal.pone.0006919.g002
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45 min, dried on Whatman DE81 paper, and visualized by a
phosporimager (Typhoon 9210, Amersham). Data was analyzed
using ImageQuant software (Amersham) and results were
expressed as the ratio between the initial fraction of DNA bound
to Topo III (f0) and the fraction of DNA bound to Topo III in the
presence of the competitor (f) as a function of the competitor
concentration in abscissa. Values correspond to the mean value of
three independent experiments 6 SD.
Cell culture
The MRC5-V1/YFP-Topo III cell line is a stable clone of the
ALT cell line MRC5-V1 transfected with YFP-Topo III [39] and
was grown in Dulbecco’s modified Eagle’s medium (GIBCO/
Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS;
Invitrogen), 10 mM L-glutamine, and 400 mg/mL of geneticin.
After transfection, cells were selected for 15 days with 400 mg/mL
geneticin and cultures were sorted by FACS analysis and further
grown in the presence of 400 mg/mL of geneticin.
Antibodies
Primary antibodies used in this work were raised against PML
(PG-M3, mouse, sc-966 Santa Cruz Biotechnology), TRF2
(4A794, mouse, Upstate Biotechnology), BLM (C18, sc-7790
Santa Cruz Biotechnology), b-actin (clone AC-15, mouse, Sigma),
active caspase-3 (IMG-144, mouse, Imgenex), c-H2AX (mouse,
Upstate Biotechnology), TRF1 (C19, goat, sc-1977 Santa Cruz
Biotechnology), and Topo IIIa (clone D6, rabbit (Wu et al., 2000)).
Secondary antibodies used for western experiments were goat anti-
rabbit and anti-mouse HRP conjugates (Upstate Biotechnology)
and donkey anti-goat HRP conjugates (Abcam). For immunoflu-
orescence experiments, goat anti-mouse Alexa fluor 488 and 568
as well as a goat anti-rabbit Alexa fluor 568 (Invitrogen) were used.
Immunoblotting was performed according to [41].
G-overhang hybridization assays
The nondenaturing hybridization assay to detect the 39
telomeric G-overhang was performed as described previously
using the (AATCCC)4 oligonucleotide [42].
Immunofluorescence
Cells were plated in 6-well culture plates on glass coverslips.
After drug treatment, cells were washed with 1X PBS (pH 7.2),
fixed with 4% paraformaldehyde, and permeabilized with 20 mM
Tris-HCl (pH 8.0), 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose
and 0.5% v/v Triton X-100 for 15 min at room temperature.
Cells were then washed twice with PBS (pH 7.2). Cells were
blocked with 1% BSA in 1X PBS for 1 hour and incubated with
primary antibodies for 1 hour to 2 hours at room temperature.
After washing with 1X PBS proteins of interest were detected by
incubation for 30 min with fluorescently label secondary antibod-
ies, then washed with 1X PBS. The nuclear DNA was stained with
0.1 mg/mL DAPI in PBS (pH 7.2) for 4 min. Cells were mounted
in Shandon Immu-Mount medium (Thermo Scientific). Samples
were observed with a DMR Leica microscope and images were
captured with a Cool Snap HQ camera (Roper Scientific)
controlled by Metamorph software (Roper Scientific). Final images
are composed of arithmetic stacks of 15–25 deconvolued images,
each 0.2 mM in z-step. Stacks of 15–30 images (16 bit grayscale)
were acquired with a z-step of 0.2 mm with low illumination
intensity. For the quantification of co-localizations, 50 nuclei were
analyzed and results represent the mean 6 SD relative to YFP-
Topo III or TRF1 foci, as indicated.
Results
Human Topo III binds to G-quadruplex but prefers single-
stranded structures
Purified recombinant Topo III interacts with single-stranded
DNA, including the telomeric G-overhang sequence [39]. Since
telomeric G-overhang is prone to form G-quadruplexes, we have
examined whether the presence of guanines repeats influences the
DNA binding of Topo III. A direct binding assay for Topo III to
the telomeric G-overhang or to a mutated sequence unable to
form G-quadruplex indicated that Topo III has a slight preference
for single-stranded DNA that cannot fold into a G-quadruplex
(result not shown). To quantify differences in binding, we have
performed competition experiments with radioactively labeled
single-stranded oligonucleotides (21G, S310 and 24C), unlabeled
DNA oligonucleotides able to form G-quadruplex (21G, Pu22myc)
or unable to form G-quadruplex (21Gmu, Pu22mu) [43,44]. The
sequences of oligonucleotides are given in the Materials and
Methods section. As an example, Figure 1A presents the analysis
of the competition for Topo III binding to oligonucleotide 24C
with either the G-quadruplex forming Pu22myc or its mutant
Pu22mu, which is unable to fold into G-quadruplex. A 3-fold
higher concentration of Pu22myc than Pu22mu was needed to
inhibit Topo III binding to single-stranded oligonucleotide 24C.
Similar differences between G-quadruplex-forming and mutant
oligonucleotides were obtained for Topo III binding to 21G and
S310 oligonucleotides (Figure 1B). The IC50s for competition with
oligonucleotides that cannot form G-quadruplex was 4.3 to 10.1-
fold lower than for G-quadruplex forming oligonucleotides in
Figure 3. Inhibition of Topo III binding to telomeric sequence
by telomestatin is due to G-quadruplex formation. A, Bandshift
assay of purified Topo III (50 nM) to [32P]-labeled 21G (20 nM) in the
presence of the indicated telomestatin concentrations. B, Bandshift
assay of purified Topo III (50 nM) to [32P]-labeled 21Gmu (20 nM) in the
presence of the indicated telomestatin concentrations. Telomestatin
had no effect on binding of Topo III to the telomeric mutant sequence
21Gmu, which cannot form a G-quadruplex.
doi:10.1371/journal.pone.0006919.g003
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PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6919Figure 4. Effects of telomestatin on Topo III signals and Topo III/TRF2/BLM protein levels in MRC5-V1/YFP-Topo III cells. A,
Representative images of untreated MRC5-V1/YFP-Topo III cells and cells treated with 2 mM telomestatin for 48 h; Topo III was detected by fluorescence
of YFP-tagged Topo III (green) or by immunofluorescence using D6 antibody (red). Dapi staining of DNA is shown in blue. Telomestatin induced a
decrease of Topo III foci number and intensity. B, Cells were treated with telomestatin (0.5 to 5 mM) for 24, 48, or 72 h and Topo III, BLM, TRF2, and actin
protein levels were detected by western blot. Telomestatin induced a dose-dependent decrease in Topo III, TRF2, and BLM. C, quantification of the
western blot experiment. Result were normalized relative to actin protein levels and expressed relative to control untreated cells, defined as 100%.
doi:10.1371/journal.pone.0006919.g004
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single-stranded oligonucleotides relative to G-quadruplex forming
oligonucleotides.
Telomestatin inhibits Topo III binding to the telomeric
G-overhang
We next determined whether ligands that stabilize G-quadruplex
formation interfere with the binding of Topo III to the telomeric G-
strand. Telomestatin was isolated from Streptomyces annulatus and
potently and selectively binds to and stabilizes telomeric G-
quadruplexes [12–14]. In these experiments, we used the Wt26
oligonucleotide previously shown to form a G-quadruplex [45]. In
the presence of telomestatin, we observed a strong inhibition of
Topo III-Wt26 complex as detected by bandshift experiments
(Figure 2A). Slight inhibition was observed at 0.03 mM telomestatin
and no complex was observed at 0.1 mM; the IC50 was 60 nM. In
contrast, telomestatin (up to 10 mM) had no effect on Topo III
binding to the single-stranded oligonucleotide S310 (Figure 2B).
TelomestatinefficientlyinhibitedTopoIIIbindingtoG-quadruplex
forming 21G (IC50 equal to 300 nM) but not to the mutant
sequence 21Gmu (IC50 .10 mM) (Figure 3A and B). We obtained
similarresultsusingotherG-quadruplexligandssuchasthepyridine
dicarboxamide derivative 360A and the steroid derivative funtu-
mine guanylhydrazone [17,46] (results not shown). We concluded
that the stabilization of the G-quadruplex structure by specific
ligands such as telomestatin efficiently impaired Topo III binding.
Figure 5. Telomestatin induces a delocalization of Topo III from PML and TRF2. Representative images are of untreated MRC5-V1/YFP-
Topo III cells or cells treated for 48 h with 2 mM telomestatin. A, Topo III detected by fluorescence of YFP-tagged Topo III (green) and PML detected
by immunofluorescence (red). Dapi staining of DNA is shown in blue. B, Topo III detected by fluorescence of YFP-tagged Topo III (green) and TRF2
detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The extent of co-localization of Topo III and PML and of Topo III and
TRF2 is decreased by telomestatin treatment relative to that in untreated cells.
doi:10.1371/journal.pone.0006919.g005
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POT1 to the telomeric G-overhang in a coupled transcription and
translationassay [42].Theuseofpurified recombinantPOT1protein
under bandshift conditions indicated that telomestatin also inhibited
the binding of POT1 to longer oligonucleotides (59-G3(T2AG3)7-39,
IC50 of 500 nM [47]) and to Wt26 (IC50 of 100 nM) (Figure 2C).
Interestingly, these values are in the same range that of telomestatin
for inhibition of Topo III binding to telomere oligonucleotides (60–
300 nM). Since telomestatin was shown to uncap POT1 from
telomeres in cell culture [42,48,49], we speculated that telomestatin
may also alter recruitment of Topo III to telomeres.
Treatment with telomestatin reduces levels of Topo III,
TRF2, and BLM and disorganizes APBs in MRC5-V1 ALT
cells
Topo III co-localizes with telomeric proteins at APBs in ALT
cells [39]. To examine the effects of telomestatin treatment on the
recruitment of Topo III to these nuclear bodies in cultured cells,
we stably transfected a YFP-tagged Topo III construct into
MRC5-V1 ALT cells [39]. Using a D6 antibody directed against
Topo III, it was shown that the tagged protein localizes at the
same sites as does the endogenous protein ([39,50], see also
Figure 4A). Therefore, it can be used to investigate the cellular
effect of telomestatin on Topo III localization. The YFP-Topo III
fluorescence signal, which mostly corresponded to large nuclear
foci, was decreased after telomestatin treatment (Figure 4A). The
immunofluorescence signal of the D6 antibody was also decreased
in telomestatin-treated cells, indicating that telomestatin alters
Topo III protein levels (Figure 4A). Further analysis by western
blot showed that Topo III protein levels were decreased by
telomestatin treatment in a dose- and time-dependent manner
(Figure 4B). After 72 hours of treatment with 2 mM telomestatin,
we observed a nearly complete loss of Topo III protein (relative to
actin). Since Topo III, BLM, and TRF2 form a complex in ALT
cells [39], we next investigated if telomestatin treatment had an
effect on the BLM and TRF2 protein levels. As shown in
Figure 4B&C, the Topo III decrease was associated with a
significant decrease in BLM and TRF2 protein levels, but there
was not significant induction of apoptosis as measured by caspase
3 cleavage (result not shown). This suggests that, like siRNA
inhibition of Topo III translation [39], telomestatin triggers Topo
III/TRF2/BLM complex degradation in ALT cells.
To further analyze the effect of telomestatin on organization of
APBs in MRC5-V1/YFP-Topo III cells, we treated cells with
2 mM telomestatin for 48 h, because these conditions measurably
reduce Topo III, TRF2 and BLM protein levels but cells remain
viable. This allowed us to perform nuclear localization studies by
microscopy. Microscopic examination of treated cells showed
important changes in the nuclear organization of YFP-Topo III at
APBs. Telomestatin reduced the co-localization of YFP-Topo III
with PMLs (Figure 5A) and with TRF2 (Figure 5B). Double
staining with anti-TRF2 and with anti-PML antibodies allowed us
to visualize these APBs components in MRC5-V1/YFP-Topo III
cells. After telomestatin treatment, YFP-Topo III, TRF2, and
PML were observed in separate foci (Figure 6). Similar loss of co-
localization was observed between YFP-Topo III and two other
factors of the shelterin complex, TIN2 and TRF1 (Figure 7 A and
B). After telomestatin treatment, only 20% of YFP-Topo III co-
localized with PML and TRF2 and only about 45% of YFP-Topo
III co-localized with TRF1 or TIN2 (Figure 8A). Interestingly,
telomestatin did not qualitatively alter the co-localization between
YFP-Topo III and BLM (Figure 8A and B); however, BLM
protein levels decreased after telomestatin treatment as shown by
western-blot (Figure 4B), suggesting that telomestatin does not
Figure 6. Co-localization of Topo III with PML and TRF2 is inhibited by telomestatin treatment. Representative images are of untreated
MRC5-V1/YFP-Topo III cells and cells treated with 2 mM telomestatin for 48 h; YFP-tagged Topo III is shown in green, TRF2 is shown in red (detected
by immunofluorescence), and PML is shown in blue (detected by immunofluorescence).
doi:10.1371/journal.pone.0006919.g006
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indicate that the G-quadruplex ligand telomestatin decreases the
amount of Topo III/BLM/TRF2 complex present in cells and
disrupts the formation of APBs.
Co-immunoprecipitation experiments were also performed to
study whether the interaction of TRF2 or BLM with Topo III is
altered by telomestatin treatment. In the complex precipitated by
the Topo III D6 antibody, we detected TRF2 and BLM by
immunoblotting (Figure S1 and [39]). After 48 hours of treatment
with 2 mM telomestatin, we observed a nearly complete loss of
TRF2 protein associated with Topo III. In contrast, BLM
associated with Topo III is not affected by telomestatin treatment.
These results confirm the immunofluorescence observations.
Telomestatin induces a massive DNA damage response
at telomeres in ALT cells
To further determine whether telomestatin-induced ABP disrup-
tion affected telomere integrity, we tested MRC5-V1/YFP-Topo III
cells for DNA damage that co-localized with telomeres. Telomere
dysfunction-induced foci (TIFs) can be detected due to the presence of
c-H2AX, a phosphorylated variant of histone 2A that associates with
DNA double-strand breaks [51]. Cells treated with 2 mM telomestatin
Figure 7. Telomestatin induces a de-localization of Topo III from TIN2 and TRF1. Representative images are of untreated MRC5-V1/YFP-
Topo III cells or cells treated for 48 h with 2 mM telomestatin. A, Topo III was detected by fluorescence of YFP-tagged Topo III (green) and TIN2 was
detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. B, Topo III was detected by fluorescence of YFP-tagged Topo III
(green) and TRF1 was detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The amount of co-localization between Topo III
and TIN2 or Topo III and TRF1 observed in untreated cells was decreased by telomestatin treatment.
doi:10.1371/journal.pone.0006919.g007
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Topo III cells were left untreated or were treated for 48 h with 2 mM telomestatin. A, Quantification of the co-localization between Topo III and PML,
TRF2, TRF1, TIN2, and BLM in untreated and treated cells. Results are expressed as the relative percentage of Topo IIIa foci that co-localize with PML,
TRF2, TRF1, TIN2, or BLM foci and were determined by analysis of more than 50 nuclei. B, Topo III was detected by fluorescence of YFP-tagged Topo
III (green) and BLM was detected by immunofluorescence (red). Dapi staining of DNA is shown in blue. The co-localization of Topo III and BLM was
not altered by telomestatin treatment.
doi:10.1371/journal.pone.0006919.g008
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PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e6919Figure 9. DNA damage response after telomestatin treatment of MRC5-V1/YFP-Topo III cells. A, Cells treated for 48 h with 2 mM
telomestatin or left untreated were examined for c-H2AX foci (green) that co-localized with TRF1 (red). B, Quantification of the DNA damage foci that
co-localized with TRF1. Results are expressed as the percentage relative to c-H2AX foci number and were determined by analysis of more than 50
nuclei. C, Cells treated for 48 h with 2 mM telomestatin or left untreated were examined for c-H2AX foci (red) that co-localized with YFP-Topo III
(green). In the magnification at the bottom the co-localization between c-H2AX and Topo III is indicated by arrows.
doi:10.1371/journal.pone.0006919.g009
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with TRF1 (Figure 9A and B). There was a background level of c-
H2AXfoci in untreated MRC5-V1/YFP-Topo IIIcells of 1466f o c i/
nucleus; only 8% (62%) of these foci co-localized with TRF1. In the
presence of telomestatin, we observed an increased number of c-
H2AX foci to 6864 foci/nucleus and almost half co-localized with
TRF1 (4664%), suggesting that telomestatin triggers a DNA damage
response that mostly takes place at telomeres. However, the analysis of
treated cells foci that contain both YFP-Topo III and c-H2AX
indicated that most of the DNA damage response was not associated
with Topo III foci (Figure 9C). We then evaluated the amount of G-
overhang telomeric DNA signal in MRC5-V1/YFP-Topo III cells
after treatment with telomestatin using solution hybridization
experiments (Figure 10). A significant reduction of the hybridization
was observed in telomestatin-treated cells (40% of the signal observed
in untreated cells). This is in agreement with other reports where
telomestatin alters telomeric G-overhang in telomerase-positive cell
lines[41,44,46]. Together, these results indicate that telomestatin
induces a massive DNA damage response at telomeres.
Discussion
Telomestatin binds specifically to G-quadruplex structures. In
cells with telomerase activity, this binding results in telomere
uncapping and leads to the G-overhang degradation and the
release of telomeric proteins (POT1 and/or TRF2). Telomere
uncapping is associated with a DNA damage response on a subset
of telomere ends (for a recent review, see [15]). Little was known
about the effect of telomestatin or other G-quadruplex ligands in
telomerase-negative ALT cell lines, except that cell proliferation is
inhibited [8,16,17,52]. The results discussed here indicate that
telomestatin induces G-overhang degradation in MRC5-V1/YFP-
Topo III cells, an effect also observed in another ALT cell line,
WI38-VA13 cells (result not shown). Our data suggest that
alteration of the conformation or length of the telomeric G-
overhang is a relevant marker for telomestatin activity in both
telomerase positive and ALT cells.
Interestingly, telomestatin provoked a massive DNA damage
response at telomeres in ALT cells, a result that contrasts with
previous finding for this compound in telomerase-positive cell lines
where only a small fraction of DNA damage foci corresponded to
TIFs [49,53]. Either telomestatin-induced DNA damage mostly
takes place in extra-telomeric regions where potential G-
quadruplex forming sequences have been identified [4] or the
G-quadruplexes stabilized by telomestatin may be tightly regulated
in telomeric regions during telomere replication. Specific G-
quadruplex resolvases may repair these G-quadruplex structures to
avoid replication blocks and DNA damage accumulation. For
example, the FANCJ helicase suppresses the DNA damage
response induced by telomestatin in telomerase-positive cells [53].
The massive DNA damage response at telomeres in ALT cells
after telomestatin treatment is accompanied by depletion of the
Topo III/BLM/TRF2 complex and by telomere uncapping.
These are the same effects observed after Topo III depletion by
siRNA in ALT cells [39]. Telomestatin treatment also disrupted
APBs, as evidenced by the segregation of Topo III, PML, and
other shelterin components into separate foci (Figure 11). A close
linkage between the formation of APBs, the presence of proteins
from the shelterin complex and telomere maintenance by
recombination has been suggested, although their structural
organization is poorly understood [54,55]. These specialized
bodies contain recombination proteins that are thought to support
the processes that maintain telomere length in the absence of
telomerase activity. Recent evidence indicates that APBs provide a
platform (called telomere clusters) where post-replicative telomere
recombination intermediates are resolved [56]. These structures
may maintain a spatio-temporal organization of telomeres needed
for the completion of these reactions. Our data are consistent with
a redistribution of unprotected telomere ends due to the absence of
the telomere bouquet after telomestatin treatment.
Figure 10. Effect of telomestatin on G-overhang signal. A, DNA was extracted from untreated MRC5-V1/YFP-Topo III cells or cells treated for
48 h with telomestatin at indicated concentrations. The G-overhang signal was evaluated by non-denaturing solution hybridization with a telomeric
probe (AATCCC)4. The gel was also stained with ethidium bromide. B, Quantification of the experiment presented in A. The G-overhang hybridization
signal was normalized relative to the ethidium bromide signal. Results are expressed as the percentage of G-overhang signal in control untreated
cells, which was defined as 100%.
doi:10.1371/journal.pone.0006919.g010
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disruption are unclear. The depletion of several components of
the shelterin complex, including TRF1, TRF2, TIN2 and RAP1
was previously shown to reduce formation of APBs [55]. Because
telomestatin impairs the binding of POT1 and Topo III to the
telomeric G-strand in vitro, the simplest explanation is that
telomestatin disrupts the interactions to telomeres of telomere-
binding proteins, inhibiting correct assembly of proteins on the
APB platform. Although TRF2 does not directly bind to the
telomeric G-overhang, G-quadruplex stabilization may induce
indirect structural alterations at telomere ends or during
replication, leading to the release and depletion of TRF2.
Several pieces of evidence indicate that TRF2 affects telomere
structure and represses homologous recombination events at the t-
loop [1]. The N-terminal domain of TRF2 was recently reported
to introduce a torsional stress in telomeric DNA, to promote
strand invasion into duplex DNA and to bind to Holliday Junction
structures [37,57]. We have proposed that Topo III might play a
general role in ALT telomere physiology by resolving TRF2-
mediated topological intermediates to modulate the t-loop
formation or to modulate recombination processes [39]. It is
likely that Topo III, which is essentially a nicking-closing enzyme
that recognizes a single-stranded DNA region, catalyzes the
resolution of the D-loop formed at t-loop or the double-Holliday
junctions formed during telomere recombination (Figure 11).
The G-quadruplex stabilization by telomestatin may interfere
with t-loop formation/dissolution or with Holliday junction
resolution at telomere ends. In agreement, in vitro experiments
indicated that telomestatin inhibited the strand invasion reaction
of a G-strand oligonucleotide into a telomeric duplex suggesting
that the ligand is able to block the t-loop formation (JF Riou,
unpublished results). The specific difference between ALT cells
and telomerase-positive cells is due to the respective presence or
absence of APBs where recombination takes place. Therefore, the
inhibition of the double-Holliday junction resolution by telomes-
tatin might be more deleterious for telomere capping than the
inhibition of the t-loop formation/resolution. However we cannot
exclude the possibility that the resolution of t-loop formation in
ALT cells represents a critical process. Our data provides a
possible clue to the important effects of telomestatin at telomeres in
Figure 11. Model for the action of telomestatin in ALT cells. Short telomeres to be elongated are present in the APB platform and capped
with proteins from the shelterin complex (Sh), including TRF1, TRF2, TIN2, TPP1, hRAP1 and POT1. The APBs also contains PML protein and proteins
from the RTR complex (RTR), including Topo III, BLM, RMI1 and RMI2. Other recombination factors are not represented for sake of clarity. Telomere
elongation takes place after homologous recombination (strand invasion); a possible mechanism for the resolution of the double Holliday junction
occurring at the end of the recombination process involves Topo III/BLM recruitment by TRF2 at telomeres. In the presence of telomestatin, G-
quadruplex stabilization induces APB disruption, which is a phenocopy of the siRNA-mediated Topo III deficiency, together with Topo III, BLM and
TRF2 depletion, exposure of telomere ends to DNA damage (uncapping) and G-overhang degradation. A magnification of the image from Figure 6 is
presented to illustrate the modification of the colocalization between PML, Topo III and TRF2.
doi:10.1371/journal.pone.0006919.g011
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Topo III controls recombination at telomeres in mammalian cells
or results from the indirect loss of TRF2 triggered by the
telomestatin treatment would be of great interest.
In conclusion, our results show that the G-quadruplex ligand
telomestatin induces a telomere dysfunction in ALT cells,
associated with APBs disruption and Topo III/BLM/TRF2
complex depletion. This emphasizes the interest of G-quadruplex
ligands as potential therapeutics in tumor cells with alternative
telomere maintenance mechanism.
Supporting Information
Figure S1 Topo III/TRF2 complex is impaired in MRC5V1/
YFP-Topo III cells treated with 2 mM telomestatin for 48 h. In
contrast, Topo III/BLM complex is not modified by telomestatin
treatment. Co-Immunoprecipitation was performed with D6
rabbit polyclonal antibody directed against Topo III as described
previously [1]. Briefly, 2610
7 cells were lysed using RIPA buffer
supplemented with 330 mM NaCl. The extract was precleared by
Protein G Sepharose 4 Fast Flow and was mixed overnight with
D6 anti-Topo III antibody. 100 ml of protein G-Sepharose beads
were added to each sample, and beads were collected by
centrifugation and washed three times with PBS buffer, eluted
with Laemmli loading buffer, and analyzed by immunoblotting
with the indicated antibodies directed against TRF2, BLM or
Topo III (see Materials and Methods).
Found at: doi:10.1371/journal.pone.0006919.s001 (0.09 MB
PDF)
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